Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| KRRO | CLUSTER | neutral | 3/10 | Four senior insiders at Korro Bio (COO, CSO, SVP Finance, General Counsel) sold a total of $180K in open-market sales on | Jun 17, 2026 |
| DYN | CLUSTER | neutral | 2/10 | Three top executives (CEO, CMO, CCO) at Dyne Therapeutics sold a combined ~$68K in shares on June 16, 2026, the same day | Jun 17, 2026 |
| SAFX | 8-K | bullish | 5/10 | XCF Global terminated a $50M equity line of credit (ELOC) purchase agreement with Helena Global, releasing approximately | Jun 17, 2026 |
| QURE | 144 | neutral | 2/10 | Director Madhavan filed Form 144 to sell 11,685 ordinary shares (~$526K) under a 10b5-1 plan adopted March 16, 2026. Thi | Jun 17, 2026 |
| UPB | CLUSTER | neutral | 2/10 | Five Upstream Bio insiders (CEO, CFO/COO, CMO, CBO, General Counsel) sold a combined ~$31K worth of UPB stock on a singl | Jun 17, 2026 |
| INMB | 8-K | neutral | 3/10 | Inmune Bio held its 2026 annual meeting and shareholders approved an amendment to the 2021 Stock Incentive Plan, increas | Jun 17, 2026 |
| LXEO | PRESS-RELEASE | neutral | 5/10 | Lexeo Therapeutics reported JAMA Cardiology publication of Phase I/II LX2006 gene therapy data in Friedreich atxia cardi | Jun 17, 2026 |
| ADTX | 3 | neutral | 2/10 | DRW Securities, LLC filed a Form 3 initial statement of beneficial ownership with the SEC, reporting 126,772 shares of A | Jun 17, 2026 |
| SPRO | PRESS-RELEASE | bullish | 8/10 | Spero Therapeutics and GSK announced FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic fo | Jun 17, 2026 |
| GSK | 6-K | bullish | 6/10 | GSK announces FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for complicated urinary t | Jun 17, 2026 |
| LABT | 8-K | neutral | 3/10 | Lakewood-Amedex Biotherapeutics filed a Certificate of Change to effect a 1-for-10 reverse stock split, reducing outstan | Jun 17, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab filed its updated Articles of Association (June 16, 2026) via a 6-K on June 17, 2026. The document is a routine c | Jun 17, 2026 |
| ANIX | CLUSTER | bullish | 4/10 | Two Anixa insiders, including CEO Amit Kumar, made open-market purchases totaling ~$60K over a 5-day window. While the d | Jun 17, 2026 |
| SLBT | 3 | neutral | 2/10 | Xu Qian filed a Form 3 initial statement of beneficial ownership, reporting 20,000 ordinary shares of SL Science Holding | Jun 17, 2026 |
| GLASF | 6-K | bullish | 6/10 | Glass House Brands deconsolidated its dual-use cannabis retail business (Glass House Retail) by selling a 10% voting sta | Jun 17, 2026 |
| GNTA | 6-K | neutral | 4/10 | Genenta Science S.p.A. filed a 6-K announcing its Ordinary and Extraordinary Shareholders' Meeting scheduled for June 29 | Jun 17, 2026 |
| ERNA | PRESS-RELEASE | neutral | 5/10 | Ernexa Therapeutics provided a pre-IND progress update on ERNA-101, its lead iMSC therapy for immunologically cold tumor | Jun 17, 2026 |
| VSTM | 8-K | bullish | 6/10 | Verastem announced positive updated Phase 1b/2a data from the RAMP 205 trial of avutometinib plus defactinib with chemot | Jun 17, 2026 |
| OCUL | PRESS-RELEASE | bullish | 6/10 | Ocular Therapeutix announced FDA alignment to submit an NDA for AXPAXLI in wet AMD in Q4 2026 based on SOL-1 efficacy/sa | Jun 17, 2026 |
| GELS | PRESS-RELEASE | neutral | 3/10 | Gelteq provided a corporate update on its pipeline progress, including plans to commence a human clinical trial in Q3 20 | Jun 17, 2026 |
| AZTR | 8-K | mixed | 5/10 | Azitra issued a CEO letter to shareholders detailing a strategic reorientation toward near-term value-creating programs, | Jun 17, 2026 |
| ELTX | 8-K | bullish | 6/10 | Elicio Therapeutics reported preliminary clinical observations from the Phase 2 AMPLIFY-7P study showing three patients | Jun 17, 2026 |
| GOSS | 8-K | bearish | 7/10 | Gossamer Bio announced final tender results for its exchange offer, with $181.1M of its 5.00% convertible notes (90.5% o | Jun 17, 2026 |
| MIRA | 8-K | neutral | 4/10 | MIRA Pharmaceuticals announced the submission of a Phase 2a clinical trial protocol to the FDA for Ketamir-2, its oral N | Jun 17, 2026 |
| CANF | 6-K | neutral | 3/10 | Can-Fite announced its participation in the BIO International Convention 2026 (June 22-25) to conduct partnering meeting | Jun 17, 2026 |
| ONMD | CLUSTER | bullish | 6/10 | Three insiders (CEO, CMO, and a Director) made open-market purchases totaling ~$210K over five days, with the CEO buying | Jun 17, 2026 |
| DYN | 8-K | neutral | 4/10 | Dyne Therapeutics expanded its Hercules Capital debt facility to $400M via a Second Amendment, borrowing an additional $ | Jun 17, 2026 |
| QURE | 8-K | bullish | 8/10 | uniQure announced that the FDA has agreed the 3-year analysis from the Phase I/II study of AMT-130 in Huntington's disea | Jun 17, 2026 |
| CANF | PRESS-RELEASE | neutral | 3/10 | Can-Fite BioPharma announced its participation in the BIO International Convention 2026 (June 22-25) to conduct partneri | Jun 17, 2026 |
| EVO | 6-K | neutral | 3/10 | Evotec SE filed a 6-K reporting that managing board member Dr. Cord Dohrmann sold €576,720 worth of shares at €4.81 per | Jun 17, 2026 |